JP2023518049A5 - - Google Patents

Info

Publication number
JP2023518049A5
JP2023518049A5 JP2022555733A JP2022555733A JP2023518049A5 JP 2023518049 A5 JP2023518049 A5 JP 2023518049A5 JP 2022555733 A JP2022555733 A JP 2022555733A JP 2022555733 A JP2022555733 A JP 2022555733A JP 2023518049 A5 JP2023518049 A5 JP 2023518049A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
cells
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022641 external-priority patent/WO2021188599A1/en
Publication of JP2023518049A publication Critical patent/JP2023518049A/ja
Publication of JP2023518049A5 publication Critical patent/JP2023518049A5/ja
Pending legal-status Critical Current

Links

JP2022555733A 2020-03-16 2021-03-16 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 Pending JP2023518049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990396P 2020-03-16 2020-03-16
US62/990,396 2020-03-16
PCT/US2021/022641 WO2021188599A1 (en) 2020-03-16 2021-03-16 Novel antigen binding domains and synthetic antigen receptors incorporating the same

Publications (2)

Publication Number Publication Date
JP2023518049A JP2023518049A (ja) 2023-04-27
JP2023518049A5 true JP2023518049A5 (cg-RX-API-DMAC7.html) 2026-06-02

Family

ID=77768273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555733A Pending JP2023518049A (ja) 2020-03-16 2021-03-16 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体

Country Status (12)

Country Link
US (1) US20230212319A1 (cg-RX-API-DMAC7.html)
EP (2) EP4592310A3 (cg-RX-API-DMAC7.html)
JP (1) JP2023518049A (cg-RX-API-DMAC7.html)
KR (1) KR20220169488A (cg-RX-API-DMAC7.html)
CN (1) CN116194130A (cg-RX-API-DMAC7.html)
AU (1) AU2021237570A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018359A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171906A1 (cg-RX-API-DMAC7.html)
IL (1) IL296411A (cg-RX-API-DMAC7.html)
MX (1) MX2022011417A (cg-RX-API-DMAC7.html)
WO (1) WO2021188599A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210400B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP7542822B2 (ja) * 2018-12-27 2024-09-02 国立大学法人京都大学 T細胞受容体の改変体
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
JP7645500B2 (ja) * 2020-05-07 2025-03-14 ブリスター イムノテック リミテッド 改善されたt細胞受容体共刺激分子キメラ
CN117843812A (zh) * 2020-05-22 2024-04-09 重庆精准生物技术有限公司 逆转肿瘤微环境的融合蛋白及其应用
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰(北京)生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
US20220089642A1 (en) * 2020-09-17 2022-03-24 City Of Hope Fc Receptor-ACE2 Conjugates and Use Thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
WO2023086379A2 (en) * 2021-11-10 2023-05-19 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN118679180A (zh) * 2021-11-15 2024-09-20 阿奇利克斯股份有限公司 包含d结构域的多肽及其用途
US20240352123A1 (en) * 2021-12-03 2024-10-24 University Of Utah Research Foundation High selective cd229 antigen binding domains and methods of use
WO2023129937A1 (en) * 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
US20260007747A1 (en) * 2022-01-07 2026-01-08 Vivasor, Inc. Engineered PD-L1-Targeting Gamma Delta T Cell Receptors
KR20240163119A (ko) * 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
JP2026501516A (ja) * 2023-01-05 2026-01-16 アンヘレス セラピューティクス インコーポレイテッド 遺伝子導入および合成および免疫受容体の活性を制御するための方法および組成物
CN115786272B (zh) * 2023-01-05 2025-02-14 厦门大学 靶向SARS-Cov-2的TCR-T的制备方法及其应用
WO2024189620A1 (en) * 2023-03-13 2024-09-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
EP4694900A1 (en) * 2023-04-13 2026-02-18 The Johns Hopkins University Engineered t-cell receptors and methods of making and using the same
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院(皖南医学院弋矶山医院) 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025213182A1 (en) * 2024-04-05 2025-10-09 The Board Of Trustees Of The Leland Stanford Junior University Combinatorial approaches for targeting hematopoietic cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
TW202617750A (zh) * 2024-07-10 2026-05-01 美商安吉利斯治療學公司 包含表位與多肽的組成物及方法
CN122071528A (zh) * 2024-11-22 2026-05-22 浙江纳米抗体技术中心有限公司 多特异性抗原结合分子及其应用
WO2026148122A1 (en) * 2024-12-31 2026-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Car with dual-variable-domain and enhanced tcr-signaling (cadet) and methods of use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP3066118B1 (en) * 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
ES2959480T3 (es) 2014-02-07 2024-02-26 Univ Mcmaster Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
PL3209698T5 (pl) 2014-10-22 2022-04-25 Crescendo Biologics Limited Mysz transgeniczna
WO2016062988A1 (en) 2014-10-22 2016-04-28 Crescendo Biologics Limited Vh scaffold
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
DE102015101304B3 (de) 2015-01-29 2016-03-17 Fujitsu Technology Solutions Intellectual Property Gmbh Rackserver für ein Serverrack
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168766A1 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
EP3380602A4 (en) 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CN110177803A (zh) * 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
WO2018148454A1 (en) * 2017-02-09 2018-08-16 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
CN106939048A (zh) * 2017-03-25 2017-07-11 康众(北京)生物科技有限公司 一种CD3ε×CD19双特异性纳米抗体及其制备方法
WO2018200582A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019006072A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
US20200207867A1 (en) 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
JP2021511782A (ja) 2018-01-31 2021-05-13 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 安定化された免疫グロブリンドメイン
MA52206A (fr) 2018-03-27 2021-02-17 Xyphos Biosciences Inc Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels
JP7599205B2 (ja) 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
LT3823990T (lt) * 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
MX428176B (es) 2019-01-28 2025-11-13 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moléculas heterólogas unidas a receptores nkg2d no naturales en células car.
IL305175A (en) * 2021-02-19 2023-10-01 Angeles Therapeutics Inc Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Similar Documents

Publication Publication Date Title
JP2021525509A5 (cg-RX-API-DMAC7.html)
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP2024518011A5 (cg-RX-API-DMAC7.html)
JP2021500861A5 (cg-RX-API-DMAC7.html)
JP2020500530A5 (cg-RX-API-DMAC7.html)
JP2023525720A5 (cg-RX-API-DMAC7.html)
JP2024059628A (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
IL297514A (en) Vectors and methods for in vivo transduction
DK2614077T3 (en) Chimeric antigen receptors with an optimized hinge region
JP2025037871A5 (cg-RX-API-DMAC7.html)
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
JP2019518424A5 (cg-RX-API-DMAC7.html)
JP2020517263A5 (cg-RX-API-DMAC7.html)
US20230390392A1 (en) Multiplex gene edited cells for cd70-directed cancer immunotherapy
JP2024519335A5 (cg-RX-API-DMAC7.html)
AU2021307614A1 (en) Engineered immune cell for allotransplantation
CA3126431A1 (en) Receptors providing targeted costimulation for adoptive cell therapy
US20210095029A1 (en) Compositions and methods for treating cancer
US20250073266A1 (en) Dosing regimens for cancer immunotherapy
JP2024510900A5 (cg-RX-API-DMAC7.html)
US20250319185A1 (en) Bcma-directed cellular immunotherapy compositions and methods
IL297547A (en) Therapeutic interventional particles for the corona virus
JP2023548829A5 (cg-RX-API-DMAC7.html)